In this setting, several low-molecular-weight radiolabeled PSMA inhibitors have been developed to improve diagnostic performances of nuclear medicine imaging and as theragnostic agents for prostate cancer patients, demonstrating an effective diagnostic compound and therapeutic agent [22,23]. Here, FOLH1 is linked to prostate cancer.